JAC-antimicrobial resistance · 2026
In vitro activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karlowsky James A, Estabrook Mark, Suzuki Eisuke, Shimizu Atsuyuki, Okade Hayato
Аннотация
OBJECTIVES: We assessed the in vitro activity of aztreonam-nacubactam and cefepime-nacubactam against a 2021-2023 global collection of clinical isolates of Gram-negative bacilli (12 613 Enterobacterales, 3748 Pseudomonas aeruginosa and 601 Acinetobacter baumannii). Nacubactam is a novel diazabicyclooctane β-lactamase inhibitor that also possesses intrinsic antimicrobial (PBP2 inhibition) and β-lactam enhancer (for β-lactams that bind PBP3 and other non-PBP2 PBPs) activities against Enterobacterales. Aztreonam-nacubactam and cefepime-nacubactam are in clinical development for the treatment of complicated urinary tract infections, acute uncomplicated pyelonephritis and various infections caused by carbapenem-resistant Enterobacterales (CRE).
METHODS: MICs were determined for aztreonam-nacubactam (1:1 ratio), cefepime-nacubactam (1:1 ratio) and 13 comparators using the CLSI broth microdilution method.
RESULTS: For all Enterobacterales isolates, the MIC90s of aztreonam-nacubactam and cefepime-nacubactam were 1 and 0.5 mg/L, respectively; 99.8% of all Enterobacterales isolates and 99.8% of CRE isolates (n = 917) were inhibited by aztreonam-nacubactam at 4 mg/L and by cefepime-nacubactam at 8 mg/L. Both aztreonam-resistant and cefepime-resistant isolate MICs demonstrated a modal decrease of 64-fold by the addition of nacubactam at a 1:1 ratio. Aztreonam-nacubactam and cefepime-nacubactam were active against the majority of Enterobacterales isolates that were resistant to aztreonam-avibactam, ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol. The MIC90s for aztreonam-nacubactam and cefepime-nacubactam were 16 and 8 mg/L for P. aeruginosa and >64 and 64 mg/L for A. baumannii.
DISCUSSION: The results of this study support the continued development of aztreonam-nacubactam and cefepime-nacubactam as potential therapies for infections caused by CRE where resistance or potential toxicity to marketed antimicrobial agents excludes their use.
METHODS: MICs were determined for aztreonam-nacubactam (1:1 ratio), cefepime-nacubactam (1:1 ratio) and 13 comparators using the CLSI broth microdilution method.
RESULTS: For all Enterobacterales isolates, the MIC90s of aztreonam-nacubactam and cefepime-nacubactam were 1 and 0.5 mg/L, respectively; 99.8% of all Enterobacterales isolates and 99.8% of CRE isolates (n = 917) were inhibited by aztreonam-nacubactam at 4 mg/L and by cefepime-nacubactam at 8 mg/L. Both aztreonam-resistant and cefepime-resistant isolate MICs demonstrated a modal decrease of 64-fold by the addition of nacubactam at a 1:1 ratio. Aztreonam-nacubactam and cefepime-nacubactam were active against the majority of Enterobacterales isolates that were resistant to aztreonam-avibactam, ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol. The MIC90s for aztreonam-nacubactam and cefepime-nacubactam were 16 and 8 mg/L for P. aeruginosa and >64 and 64 mg/L for A. baumannii.
DISCUSSION: The results of this study support the continued development of aztreonam-nacubactam and cefepime-nacubactam as potential therapies for infections caused by CRE where resistance or potential toxicity to marketed antimicrobial agents excludes their use.